{
  "document_id": "5a5bc29d",
  "zip_file": "hjnw0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "hjnw0257.pdf",
    "file_path": "Presentations/hjnw0257.zip/hjnw0257.pdf",
    "extracted_text": "=== Page 1 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 1 Image 1 (OCR) ===\n& Company EEE Wy\n\nCorporate\nperformance\ndiagnostics\n\nDiscussion document\nMarch 2020\n\n@endo Y L\n\ntd J Wh\neg / f\nOLE DEE T AL ALD PROPR E TARY. FAP SES J\nAng) asi Dns ake gs wltcabsres Dorin seca PR: Kosin Rss ran OC ae Sf bs ff)\nssbety pratt Ct ho\n\nMCK-MAAG-2627981\n\n=== Page 2 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 2 Image 1 (OCR) ===\nKey issues\n\n.\n\nOpioid: Company is facing litigation related to opiaid overuse across many states in US Settled liabilities with\n\nOklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B - 4 0B\n\npete tate tere erate et ete a erate a ete ere ete a eR RR RR eR RI RR en eR ne ne nn A nnn A ne a eine a ene eine eimai mie ereierereeierermierete\n\nLegal\n\npict c enter eter eres\n\nRedacted\n\nRedacted\n\naerate eee eee eee ere ein eee ee ee ee eRe ee ne nn ne A nn RR en nin RI ee ne a nie nia en ne niente eee nie mia ere ereiereierermi eet\n\neine teeter eee\n\nsor\n\nvntovy\n\nMcKinsey & Company\n\nMCK-MAAG-2627981.000001\n\n=== Page 3 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 3 Image 1 (OCR) ===\nSummary\n\n* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\npete re rere ete re te Dieta eter ret eve ei brores\n\ni\n\ni\n\nbore cere eer ege a eis pe ieie tisegiese.\n\nRedacted\n\n'growth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\npeter ete eee eee ete ee ee Re SR Rn RR RR eS A RR Re RR RR RR Re a Re a ee a a ee A a eae a nea ea eieeaeieaeinimiaiermareimeia\n\nCompany is tating large potential litigation liabilities\n\nRedacted\n\naime teint eter ete eter e tere ete eer ererereierererete:\n\nieee tere eter eter rete a ete ere ete a ete ee a ee ee ne RR ee A nn RR en A nn RR ee Rn a ee ee ne nie aie ein ete eee nina eieeieieimeieieeiaiermarereeie\n\nMcKinsey & Company\n\n6 September 2020\n\nMCK-MAAG-2627981 .000002\n\n=== Page 4 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 4 Image 1 (OCR) ===\nSummary\n\nnally\n\nh higher margins than peers. However, due to issues related to\n\n* Endo is well performing ope\n\n‘\n\nR\n\nopioid crisis\n\nFhe eee eee ee re a ee eee\n\n<\n\ngrowth is negative, cash flow did not cover liabilities, debt is\n\nbelow investment grade and company\n\n‘acing large potential litigation liabilities\n\npeer e ete e ee eeeeeeREeREREEmEmeeEen Cm m emer tmem mie:\n\nRedacted\n\nite teint eet eee te erate eee ere ete ee en ee ee ee RR Rn en RR nn RR ne A RI RR en eR Rn nn ne A nn nn ee a nie min eee eimai era eimeiarereiererermierermieiere\n\nMcKinsey & Company\n\n6 September 2020\n\nMCK-MAAG-2627981 .000003\n\n=== Page 5 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 5 Image 1 (OCR) ===\nEndo’s share price has declined ~90% in last 5 years mainly driven by\n\nlegal challenges and underperformance\n\nEndo share price’\n\nUSD per share\n\nee ees\n\naca mre se imra amie aim  anesarmlarararey\n\n.\n\nSSS eae\n\n120\n\nMar ‘16: Sued by FTC along\n\nwth others ‘or illegally blocking\n\nRedacted\n\nRedacted\n\nRedacted\n\nprererm sens mseae’\n\nlower-cos: generic versions of\n\nranded drugs Opana\n\ni\n\n!\n\ni\n\n=. aa\n\nRedacted\n\nUipieierm ming pimieieieiereeimiereieeiedd\n\nLerminces wqemsn term sm ime nems -\n\n|\n\n|\n\n|\n\ncetera tei erate terete terete\n\n80\n\npatotavavetaiara ate vevaraeerare\n\nJun ‘17: Sued by Ohio Asorney General\n\npete tetera terete\n\nalongwith ‘our other pharma companies ‘or\n\nRedacted\n\n‘heir alleged par: in dnung an opioid and\n\nPrescnpion painkiller overdose epidemic\n\ni\n\nect ete reer eter eter eines\n\ni\n\ni\n\nRedacted\n\n2\n\nRedacted\n\nalate ere iote eral\n\n|\n\naiaie nsaiota micas nraia ieee\n\n!\n\nthrough aggressive marke'ing ‘ac‘ics\n\n40 -\n\neine tetera tere terete eerie:\n\nJun 17: FDA reques's.\n\npain medication, Opana\n\nEndo ‘o rerrove rs opioid\n\nER, ‘ror the marke:\n\ni\n\nRedacte\n\n|\n\nieee te eee terete re reree\n\nJan 15\n\nJul 15\n\nJan 16\n\nJul 16\n\nJan 17\n\nJul 17\n\nJan 18\n\nJul 18\n\nJan 19\n\nJul 19\n\nJan 20\n\nt\n\n7A bet\n\n77\n\ns:\n\ny\n\nSAP Capla Tet rays s\n\nMcKinsey & Company\n\ni]\n\nMCK-MAAG-2627981 .000004\n\n=== Page 6 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 6 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne Ene rn SEnE ESSERE SS SEnE SSDS nSSnE SESE SERS SES SE SERENE SESE SERS SESS SERSSnS SE SESEES DSSS SERESRESOSEASSRESHSSESERESNSSHSnSSRESNSESSSRESSSSHSSESSRESSSSESERSNSSHSRSSRSSSSESERSSSESESSESSSESSSSESERSSSSHSSESSnSSSSESSRESNSSISSESSEE SOSH SESSSESSHSESSESSHSSESSnSNSSHSSISSRESHS=NSInSSNSSOSSnSSRSSESSNSTSSSnESESESERESHSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSNSSHSSSSESSNE SE SESSEE DESDE SEESONSSOS\n\nAAG-2627981.000005\n\n=== Page 7 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 7 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena rn SEn ESSE Sn SEnE SSS SEn ENE SESn SERS SESS SERSSnE SESE SERS SESS SERSSNSSESNSEESSNSSESERSNESOSEESSRESHSSESERSSNSSESnSSRESSSESSRSSSSSHSEESSRESSSESEnSSNSSISSESSESSSSNSERSSSESHSSESSSESSSSISSnSSNSSHSSESSnSSSSNSSSESNSSUSSESSnE SSSI SERSESSHSnSSESSHSSESSnSNSSHSSnSSRE SSSA SInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES DSSS SSSESNS DS SERSSRSSHSSNSISESNE SE SESSES DESDE SERSONSSISS\n\nAAG-2627981.000006\n\n=== Page 8 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 8 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner Ene rn SEn ESSENSE SERS nS SESE RENE SESE SERED SSE SERSSNE SESE SERS SESE SERSSnS SES EESEESSSSESERESNESOSEESSRESHSSESERSSNSSESRSSRESSSESSRESSSOSSESSRESHSSESERSNSSHSESSRS SSDS SERSSSESESSnSSSESSSSSSERSSSSHSSESSnSSSSESSSSSNSSISEASSnESSSESESSSESSHSESSESSSSSSSSSNESHSEASESESN SSE SInSSNSSUSSRSSRSSESSNSTSSSNESESESERESHSSSSTESSSESHSnSSESSSSESSSESNS DS SEnSSRSSHSSNSISSSNE SE SnSSEE DESDE SEESSNSSISS\n\nAAG-2627981.000007\n\n=== Page 9 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 9 Image 1 (OCR) ===\nEndo's revenue profile has remained flat and declined since 2016 driven\n\nby both Branded and Gx segments\n\nEndo's Revenue evolution by segment, 2014-19, USD bn, as reported\n\nSie ratSiciesa re tcie eS\n\nieee tere eter erate rere rererereie,\n\nRedacted\n\n@ Granded Phamral\n\na ra\n\ni 1 Genenc 2harra i\n\netorcceisrecdretetecaietatasciaiaesd\n\nGrowth (2014-19),\n\nKey takeaway\n\nCAGR SE\n\na Ste tereiarersreresesereserery\n\ni\n\ni\n\n40\n\nRedacted\n\n8% p.a.\n\n10% p.a.\n\nLn areuprninierersieieieiesere!\n\n33\n\n35\n\nBranded Pharma portfolio\n\ndeclining, driven by loss of\n\n29\n\n29\n\n29\n\nNA\n\nmarketing exclusivity for\n\n|\n\ncertain drugs and voluntary\n\nwithdrawal of OPANA® ER\n\na\n\nfrom the market since\n\nFY2017\n\nFee erate erase ra areca ra a eaey\n\n26\n\nog\n\n23\n\n03\n\nRedacted\n\n05\n\n03\n\n02\n\n20°4\n\n20°9\n\neine tetera e terete tere rerererered\n\niene ee ere Nee ee eee ere elm ielem rere seers\n\n‘\n\nRedacted\n\nMcKinsey & Company\n\n)\n\nLiece eee ee ete ee ere ete eee erate a ere ere ete eee ere ete eee areata a ee aimee eee ere eierereierermrmreretey -!\n\nMCK-MAAG-2627981 .000008\n\n=== Page 10 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 10 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner nE rn SEnE ESS EnE SSE SEnE SSDS RENE SESE SERE SESS SERSSnE SESE SERS SESS SERSSnESESESEES DSSS SERSRESUSEASSRESHSSISERSSNSSESnSSRESSSSSSRESSSHSSESSRESHSSESERSNSSHSERSSRS SSSI SERSSSESESSESSSESSSSI SERENE SHS SESSnSSSSESSRESNSSHSEASSRESSSNSERSSNSSHSESSRSSOSSESSSSNSSHSSISSRESHSSNSInSSNSSHSSRSSRSSESSNSTSSSNESESESSRESSSSSSTESSSESHSnSSESSHSEESSSESNS SS SEnSSESSHSSNSISSNE SE SnSSEOSSSSESEREONSSOSS\n\nAAG-2627981.000009\n\n=== Page 11 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 11 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnee rn SEn ESSERE SSE SEnE SSDS RENE SESE SEnE SESS SERSSnE SESE SERS SES SESERSSNS SES EESEES DSSS SERSRESOSEESSRESESSESERSSNSSESSnSSRESNSESSSRESSSHSSESSRESSSNSERESNSSHSESSnSSSSNSERSSSSSOSSESSSESSSNSEnSSSSHSSESSnSSSSNSSSESNSSUSEASSRESSSESERSSESSHSESSESSHSSESSSSNESHSSESSRESHSSNSTnSSNSSOSSRSSRSSESSNSTSSSNESSSESERESSSSSSTESSSESHSnSSEOSSSESESESNS DS SEnSSRSSHSSNSSNSSNE SES ESSRSSSSSESEESSSOSS\n\n=== Page 12 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 12 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnen EnE rn SEnE ESSENSE SEnE DOSS SE RENE SESE SERS SESS SERENE SESE SSNS SESS SERSSnSSESnSEES SSSI SERSRESOSESSRESHSSESERSSNSSESnSSRESSSESSRESSSSHSERSSRESSSESERSNSSHSSRSSRSSHSSN SERENE SOS SESSSESSSNSEnSSNSSHSSESSnSSSSNSSRESNSSISSESSRESHSSESERSNSSHSESSRSSNSSESSSESNSSHSSISSRESNSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSEESSSESNS DS SEnSSRSSHSSNSISSNE SE SESSRS DESDE SERSONSSOS\n\n=== Page 13 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 13 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner Ene rn SEnE ESSERE SSE SERE SSS SERENE SESE SERS SES SE SERENE SESE SERS SESS SERSSNESESASEESSOSSESERSRESOSESSRESHSSISERSSNSSESESSRESOSSSSSRSSSSHSEASSRESSSESERSNSSHSTnSSRS SOSH SERENE SO SSnSSSESSSISERSSNSSHSSESSRSSSSSESSnESNSSHSEESSRESHSSESESSSNSSHSESSEESSSESSnSNSSHSSRSSRESHSSNSTnSSNSSUSSRSSnSSESSNSTSSSNESESESERESHSSSSTESSSE SHS TnSSESSNSEESSSESNE DS SEnSSRSSHSSNSISSSNE SE SnSSRS DESDE SEESONSSOS\n\n=== Page 14 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 14 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE SSS SERENE SESE SEnE SESE SERSSNE SESE SERS SESS SEnSSnSSESESEES SSSI SERSRESOSESSRESHSSESERSSNSSHSnSSRESSSESSRESSSHSEESSRESHSSESERSNSSHSESSESSOSSESERSSSESUSSESSSESSSISERSSESSHSSESSRSSSSSSSRESNSSISEESSnESSSESERSSESSHSnSSRESOSSESSSSNSSHSSASSEESNSSNSInSSNSSUSSRSSNSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSRSSHSSNSESSNE SE SESSRS DESDE SERSOSSOSS\n\n=== Page 15 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 15 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTn ern ne rn SEnE ESSENSE SERS nS SE RENE SESE SEnE SESS SEnSSNE SESE SERS SESS SERSSnS SES EnSEES SSS SSRSRESUSEASSRESSSESERSSNSSESnSSRESNSESSSRSSNSSHSSESSRESHSSESERSNSSISRSSES SOSH SEnSSSESESSESSSESSSESERSSSSHSSESSRSSOSSESSSESNSSISSESSnESHSSESERSSESSHSnSSRSSNSSSSSSESNSSHSSnSSEESSSNSEnSSNS SOS SESSRSSESSNSTSSSNESSSESERESOSSSSTESSSESHSnSSESSNSSNSESESNS DS SEnSSRSSHSSNSISSNE SE SESSRSSSSDESERSNSSIS\n\n=== Page 16 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 16 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner rn SEnE ESSENSE SERS SOS SEn SESS SERS SES SESERSSNE SESE SERS SES SESERSSNESESESEES SSDS SSRSRESUSNSSRESSSESERSSNS SH SnSSRESNSSSSSRESSSHSEESSRESHSSESERSNSSHSESSnS SOSH SEnSSSESESnSSSESSSISERSSNSSHSSESSRSSSSESSSESNSSHSSESSRE SSSI SERSESSHSnSSESSSSSSSnSNSSHSSISSEESHSSNSInSSNSSOSSRSSRSSESSNSTSSSNESESESSRESSSSSSTESSSESHSnSSEESNSENSSSESNS DS SERSSRSSHSSNSESSSNE SE SnSSRS DESDE SEESNSSISS\n\n=== Page 17 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 17 Image 1 (OCR) ===\npine tee tererere,\n\nEndo also has large potential litigation liabilities up to UST recacte\n\neine tected\n\nEstimate\n\nLiability\n\nOpioid\n\n\"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement\n\nimplies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020\n\n\"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B\n\nmista teeter eee te erate teeter rere ele ere creer iber a: Date cre tie a Perma aia ee NU a ete iaid ete irerb Sree ere aie ere ee eee ereeieieeierermiereieieiay ‘\n\nopioid charges paid over 10 years.\" - Guggenheim, Nov 5, 2019\n\ni\n\ni\n\ni\n\ni\n\nRedacted\n\nbien re eee eee ee ere eter et ete eee a ete eee ete ete ee ee ee a nn eR ee a nn nn en A nn ee ee a ne nie nie eine nie aie aimee eee aimee eeiereimrerererey =\n\nsor\n\nssp\n\nvila og Areal:\n\nrl\n\nvt\n\nMcKinsey & Company\n\n7\n\nMCK-MAAG-2627981 .000016\n\n=== Page 18 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 18 Image 1 (OCR) ===\nOpioid portfolio currently consists of Percocet” that contributes\n\n~14% of Branded Pharma and 4% of company revenue\n\n\"PERCOCET™. which is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain\n\nThe Company's pain products, including opioid products. are managed as mature brands and are not and have not been actively promoted for years. In\n\nDecember 2016, the Company announced the elimination of its entire U.S. pain product field sales force\n\nGeneric Pharmaceuticals The Generic Pharmaceuticals segment includes a product portfolio of approximately 150 generic prescription product families\n\nincluding solid oral extended-release. solid oral immediate-release. liquids, seni-solids, patches (which are medicated adhesive patches designed to deliver the\n\npharmaceutical through the skin), powders. ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions) and sprays and\n\nincludes products in the pain management. urology. central nervous system disorders, immunosuppression, oncology. women’s health and cardiovascular disease\n\nmarkets, among others\n\n- 10K 2019\n\nRevenue in USO M\n\n2019\n\nPercocet\n\n116\n\nBranded Pharma\n\n855\n\nPercocet as % of Branded Pharma\n\n14%\n\nEndo total revenue\n\n2.914\n\nPercocet as % of Endo total revenue\n\n4%\n\nsor\n\nwn tov)\n\n18\n\nMcKinsey & Company\n\nMCK-MAAG-2627981 .000017\n\n=== Page 19 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 19 Image 1 (OCR) ===\nSummary\n\n. Endo i is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\nmonte tere erate eie ere ere etete Bietdie rete\n\njac\n\nin pete tetera tate rere rete tere eter ererereieres\n\n‘growth i is negative, cash flow did not cover liabilities, debt is below investment grade and\n\ncompany is facing large potential litigation liabilities\n\nite teint eter ete eee ere ete eee ere ete eee Re ete ee RR en Rn eR RI RR nn RR RR nn Rn ne A ne a ne ete ee a nie mere mie nie miei ei miereeiererer eerie\n\nRedacted\n\nite teint eter ete eee ere ete eee ere ete eee Re ete ee RR en Rn eR RI RR nn RR RR nn Rn ne A ne a ne ete ee a nie mere mie nie miei ei miereeiererer eerie\n\nMcKinsey & Company\n\n19\n\n6 September 2020\n\nMCK-MAAG-2627981 .000018\n\n=== Page 20 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 20 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE SSS SERENE SESE SEnE SESE SERSSNE SESE SERS SESS SEnSSnSSESESEES SSSI SERSRESOSESSRESHSSESERSSNSSHSnSSRESSSESSRESSSHSEESSRESHSSESERSNSSHSESSESSOSSESERSSSESUSSESSSESSSISERSSESSHSSESSRSSSSSSSRESNSSISEESSnESSSESERSSESSHSnSSRESOSSESSSSNSSHSSASSEESNSSNSInSSNSSUSSRSSNSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSESSNSSESESESNS DS SEnSSRSSHSSNSESSNE SE SESSRS DESDE SERSOSSOSS\n\n=== Page 21 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 21 Image 1 (OCR) ===\nFuture cash flows from operations would be used up for litigation\n\nand interest charges and debt repayments\n\nCumulative cash flow, FY2020-24, USD bn\n\nUpside case\n\nDownside case\n\noe ta eta ase ete a eter asa re tala arate se ata aia asain ie a aierat a arate: a ates e erates a arate are,\n\nCFO betore interest |\n\nJimi Siesta Simin siminra Ss ieinre sre ei erie te rpidtniaemis winter sin inia siniarpeaemincmsss lass\n\nRedacted\n\nAssumptions:\n\npada sn a ane\n\n& changes in WC\n\n|\n\nLrigation charges\n\nof\n\n|\n\nRedacted\n\nhate ieietataietminraretaieiajeiainiaeimietseieiais setae ta ieiataiaiaiasd areieiaiaseiaintascimsetaeietsisseieis siete,\n\n-\n\nLcieinieereiase.eieiarn ereiave eeiate crete ae wiasaeereins -\n\n!\n\nOpioid litigation liability estimated to range from\n\nUSD 500M In Upside case to USD 4.0B in Downside\n\ncase (based on analyst reports), assumed to be\n\nSa aie EERE ne ee aaa ee ee\n\nrepaid by FY2024\n\nRedacted\n\nRedacted\n\nLcrerereseserarerereiesesereerereresesererntereresesererereseres <\n\nphe a\n\nate rere re saree te reretasese arn retar esate a arate as e.e a arate asesala arate aiesatarn tata a.eseraareseaseserararere\n\nMcKinsey & Company\n\n21\n\nYen ce can se ce ee oe a a a a oe se se oe a ee ee ee re oe eee ee seem ee eee ares -\n\nRedacted\n\nieee te eter ete re ere ete ete a ere ere ete ne eR a etn ee eR Re mR nn RR nn RI eR Re IR RRR Re RR nn RR RR ne A Re RR ne A Re ne ee a ne ee en ee nin eee ee a neie nee nineieieieiaeimieieeiaiereererereiered\n\nMCK-MAAG-2627981 .000020\n\n=== Page 22 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 22 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nE rn SEn ESSENSE SEnE SSS SERENE SESE SEnE SES SE SERENE SE SEESSnS SESS SERSSNSSESASERS SSDS SERSRESOSEESSRESHSSESERSNSSHSnSSRESSSSSSRESSSHSERSSRESSSESERSNSSHSRSSRSSHSSESERSSSESOSSESSSESSSSNSERSSSSHSSESSnSSSSESSSESNSSISEESSRESHSSESTnSSESSHSnSSRESHSSESSnSNSSHSSnSSRESSSNSEnSSNSSUSSESSRSSESSNSTSSNESESESERESSSSSSTESSSESHSnSSESSNSSESESESNS SS SRSSSSSHSSNSESSNE SES EESSEE DESDE SEESONSSISS\n\n=== Page 23 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 23 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE SSS SEnEnE SESE SERE SES SESERSSNE SESE SSNS SES SESERSSnSSESnSEES DSSS SERSRESHSESSRESHSSESERSSNSSHSSnSSRESNSSSSSRSSSSHSSESSRESSSESERSNSSHSESSESSSSNSERSSSSSOSSESSSESSSSSERSSSSHSSESSRSSSSSESSnESNSSHSEASSnESSSESERSSNSSHSnOSES SSDS SSSSNESHSEASSEESHSSNSInSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES SSSI SESESNS DS SEnSSRSSHSSNSEnSSNE SE SESSES SESS SESSSSOSS\n\nAAG-2627981.000022\n\n=== Page 24 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 24 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena EnE ncn ESSENSE SEnE SSDS RENE SESE SEnE SESS SERSSNE SESE SERS SESS SERSSNS SES EESERS SSDS SERSRESOSESSRESSSESERSSNSSESESSRESNSESSSRESSSHSSESSRESSSESERSNSSHSRSSESSSSNSERSSSSSESSESSSESSSSNSEnSSSSHSSESSRSSSSESSRESNSSISSESSnE SSSI SERSSESSHSESSRSSSSSSSSSNSSHSEASSSESHSSNSTnSSNSSOSSRSSRESESSNSTSSSNESESSESERESHSSSSTESSSESHSnSSEOSNSSESESESNS DS SEnSSRSSHSSNSISESNE SE SnSSEE DESDE SEESSSOS\n\nAAG-2627981.000023\n\n=== Page 25 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 25 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE OSSD RENE SESE SERS SES SESEnSSNE SESE SERS SES SESERSSNSSESESEESSOSSESERESnESOSASSRESSSESERSSNSSHSnSSRESNSSESSRESSSHSEESSRESSSESERSNSSHSESSRSSSSESEnSSSESESSESSSESSSESERSSSSHSSESSnSSSSSSSnESNSSHSEASSnE SSSI SERSSESSHSTESSRESSSESSSSNSSHSSISSEESH SSN STnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESNSSESESESNS DS SERSSNESHSSNSISSSNE SES ESSES DESDE SERSOSSISS\n\nAAG-2627981.000024\n\n=== Page 26 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 26 Image 1 (OCR) ===\nFel aentabeentebeliinenrententenbenaenbabmanoenzentabeentebaentanbenoenaa™=\"<deamante’*shaenaenteabenelnete-saeeinentantentenmetaieenetmtanaieiaianemeermnaanemtieee\n\nAnalysts are concerned about Endo's ongoing opioid litigations,\n\nRedacted\n\nsree eet olor ys aia re is ofa eis Slates eiare1s Siereie loses Stores Sto reus ota mie aia reuse oie e is Sines Siete r=\n\nSiateie Siereis Siete ys fore is Stam ys-siare ys Sia reie aia hus Siareis Sine,\n\n©. We are becoming more positive on ENDP from an opioid standpoin\n\npatdvateresdiatlacet sta aveiite tase lai aiare dlatatardtalatalavetatetiieteterSteataversia ecard!\n\nRedacted\n\nRedacted\n\nieee tere eter eee ere eee re ere ere eierereie areata eee ere eierereierererere:\n\n[i a ae ee a ee =\n\nGabelli, 14 Jan 2020\n\n[ater Ste tevercieiaretSaieietcieietatsiaietetsialele setae cia leeiiieisretdjalstetcieisletcveleesietatestetavesieiaversteid\n\npetite eter eter eet rete mieny\n\nee a\n\nRedacted\n\na oe\n\nRedacted\n\nieee ee ree ee ee ee ete te ee et ee eee ee mm e meme  mem mmem mtmem re\n\n' However, ENDP st Redacted\n\na a is\n\nand ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock\n\nRBC capital markets, 5\" Nov 2019\n\npiesa ler bface debra ia ietye ia terbyacele apeiete npeisie niece en yela er byaceie bine te reyacetertyaceyee\n\naeeeee\n\n=.=!\n\n' However, we continue to expect this dynamic to be\n\navsrahadawed by the ongoing opioid saga, which in our view remains a very significant risk given the company's branded\n\nFEES I SSSI SET SENSO CENCIO IOS aE NTES SSS NCRSES SSS SuESnISSSOOSSOE NSE SEISECE NCE OLIIC SS Es SEO -osNCIOEDISSISNCESSSOCOIES Cis SOOESSENCEISOSE SOE CIOS SOLED CSO SOE SESS\n\nopioid Portfolio/mkt share }\n\nRedacted\n\ni\n\ni.\n\nRedact\n\naie Pe ae A ery eR Oe RO IRE AE NET EL TOI EE BLO IRE OO ee emia remem terme!\n\ni\n\nJP Morgan, 5‘ Nov 2019\n\nSow\n\nvail\n\n1\n\nMcKinsey & Company\n\n26\n\nMCK-MAAG-2627981 .000025\n\n=== Page 27 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 27 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnner nE Sn SEn SSSR SEnE SSE SEnE SSE SERENE SESE SEnE SESS SERSSnE SESE SSNS SESS SERSSNSSESESEES SSDS SERSRESOSEESSRESESSE SERENE SE SnSSEESNSSESSRSSNSSHSEESSRESSSESSRSNSSHSRSSESSSSESEnSSSESESSESSSESSSNSERSSSSUSSnSSnSSSSSHSSSSSNSSISEASSRESHSSESTRSSESSHSESSRESSSSSSSSNSSHSERSSSESHSSNSEnSSNSSOSSRSSnSSESSNSTSSSNESSSESERESSSSSSTESSSESHSnSSESSSSESSSESNS DS SEnSSNESHSSNSISSNE SE SESSSESSSSESEREOSSOSS\n\nAAG-2627981.000026\n\n=== Page 28 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 28 Image 1 (OCR) ===\nSummary\n\n* Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\npare ie eee ect e sierra miei eieteteres\n\ni\n\nbaer te ete eee igi e te gin teseeteie pore\n\nRedacted\n\ngrowth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\ncompany is facing large potential litigation liabilities\n\nime ieee mieten rere tere ete ee ete ee en ee Re eR ne RR en eR Rn RR nn eR RI RR ne RR nn Rn RR RI eR nn Re ee ee nn ein ete eine eer eiaieimi ernie mime eie\n\nRedacted\n\nieee tere eet a ete a ere rete ete ere ere a ete eee nie eR ne RR ee A en RR ne Re RR Re eR nn RR ee Re ne ein ee nie a ein aie ein a aie eta eimaieimieierermimreiereie: i\n\nMcKinsey & Company\n\n28\n\n6 September 2020\n\nMCK-MAAG-2627981 .000027\n\n=== Page 29 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 29 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnnn nner SERS SEEDS SERS nS SESE nEnE SESE SEnE SESS SERSSNE SESE SSNS SESS SERSSnSSESESEES SSDS SERSRESHSESSRESHSSESERSSNSSESESSRESSSSSSRSSSSHSEESSRESESSESERESESSHSSESSRSSHSSN SERENE SE SSnSSSESOSSSSERSSSSHSSESSRSSSSNSSRESNSSISEASSnESSSESERSSNSSHSESSESSSSESSSSSNSSHSEESSRESH SSN SEnSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSES SSSI SESESNS DS SERSSNSSHSSNSISSNE SE SESSEE SESE SERSOSSOS\n\nAAG-2627981.000028\n\n=== Page 30 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 30 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena EnE ncn ESSENSE SEnE SSDS RENE SESE SEnE SESS SERSSNE SESE SERS SESS SERSSNS SES EESERS SSDS SERSRESOSESSRESSSESERSSNSSESESSRESNSESSSRESSSHSSESSRESSSESERSNSSHSRSSESSSSNSERSSSSSESSESSSESSSSNSEnSSSSHSSESSRSSSSESSRESNSSISSESSnE SSSI SERSSESSHSESSRSSSSSSSSSNSSHSEASSSESHSSNSTnSSNSSOSSRSSRESESSNSTSSSNESESSESERESHSSSSTESSSESHSnSSEOSNSSESESESNS DS SEnSSRSSHSSNSISESNE SE SnSSEE DESDE SEESSSOS\n\nAAG-2627981.000029\n\n=== Page 31 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 31 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nTn ern EnE DS nSEnE DS EnSE RSENS SS ESEnESnSSESERSERESESnSSnSSHSSESESSSNSSUSESSnSSHSSISSnSSNSSUSEESSRESISSISSRSNSSHSIRSSEESHSSISSRSSNSSHSSRSSEESHS=NSSRSSNSSHSRSSRESHSSNSERISNSSHSSNSSESSHSSNSEnSSSSHSSNSSSOSISSNSERSESSHSnSSEOSISSNSERESNSSHSNSSEESHSSESERSSNSSHSESSESSHSSISERSSNSSHSNSERESHSSNSENSNSSHSRESESSHSSNSTSSSNESHSESERESNSSESTESNESHSIRESEOSNSSESESESNSDSSEnSSESSHSSNSISSSNS DE SnSSES DESDE SESESNSSOS\n\nAAG-2627981.000030\n\n=== Page 32 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 32 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nTne Sane DS nSEnE ES DESEnSEnE SS EESEnESSSESERSEnESESnSSnSSESSESESSSNSSESESSESSHSSISTnSSNSSUSEISSRSSISEISSRSNSSHSIESSRESHSSNSSRSSNSSHSSRSSEESHSENSSRSSNSSISRSSRESHSSNSERISNSSHSIRSSESSHSSNSERSSSSHSSnSSEOSISSNSENSESSHSNSSROSISSNSIRESNSSHSNSSEESHSSHSERSSNSSHSESSRSSHSSESSRSSNSSHSESERESHSENSEnESNSSHSEESEOSESENSTSSSEESUSESERESNSSESTESSNESHSInESEOSHSENSSSESNSDSSEnSSEOSHSEISINSSNS DH SERSSESSSSDESESONSSIS\n\nAAG-2627981 .000031\n\n=== Page 33 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/hjnw0257\n\n=== Page 33 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nCnn nen Ene rn SEnE SSE EnE SSE SEnE SOS S RENE SESE SEnE SESE SERENE SESE SERS SESE SERSSnSSESnSEESSOSSESERSnESOSNSSRESHSSE SIRENS SESnSSRESSSESSRESSSHSERSSRESHSSESERSNSSHSnSSnSSSSNSERSSNSSOSSESSSESHSSNSEnSSSSHSSESSnSSSSESSRESNSSISEASSRESSSESESSSNSSHSESSESSSSESSnSNESHSEISSRESSSNSInSSNSSUSSRSSROSESSNSTSSSNESESESSRESSSSSSTnSSSESHSnSSEESNSSNSESESNS DS SEnSSESSHSSNSISSNE SES EESSES DESDE SERSNSSISS\n\nAAG-2627981.000032",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 24600,
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "hjnw0257-info.pdf",
    "file_path": "Presentations/hjnw0257.zip/hjnw0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - hjnw0257 - Downloaded 31/03/2025 11:11:14 AM\nDocument Information\nTitle: PowerPoint Presentation\nURL: https://www.industrydocuments.ucsf.edu/docs/hjnw0257\nAuthor: Manoharan Dillibabu\nDocument Date: 2020 March 02\nType: Presentation\nGenre: Microsoft Office PowerPoint Open XML Format\nPages: 33\nID: hjnw0257\nCollection: McKinsey Documents\nDrug: Oxycodone; Oxymorphone\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-2627981\nRedacted: yes\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nManoharan Dillibabu. PowerPoint Presentation. 2020 March 02. McKinsey Documents. \nUnknown. https://www.industrydocuments.ucsf.edu/docs/hjnw0257",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 758,
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:13:17.773162"
}